LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
LIFECORE BIOMEDICAL, INC. DE
Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026
$6.39+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Lifecore Biomedical, Inc. De statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Market Cap | $241.88M | $166.30M |
| Enterprise Value | $225.61M | $88.19M |
| PS Ratio | 1.88 | 3.65 |
Enterprise value
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| EV / Sales | 1.75 | 2.51 |
Income (trailing twelve months)
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Revenue | $128.87M | $58.34M |
| Gross Profit | $40.30M | $105.94M |
| Operating Income | -$17.25M | -$21.40M |
| Pretax Income | -$38.67M | -$14.34M |
| Net Income | -$38.72M | -$22.46M |
| EBITDA | -$9.22M | -$16.91M |
| EPS (Diluted) | -$1.27 | -$0.83 |
Margins
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Gross Margin | 31.3% | 52.9% |
| Operating Margin | -13.4% | -44.0% |
| Pretax Margin | -30.0% | -13.3% |
| Profit Margin | -30.0% | -40.2% |
| EBITDA Margin | -7.15% | -30.2% |
| FCF Margin | -10.6% | -9.27% |
Returns
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Return on Assets (ROA) | -16.9% | -40.9% |
| Return on Capital Employed (ROCE) | -8.30% | -38.1% |
Growth
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 5.02% | 2.25% |
| Revenue Growth (5Y CAGR) | -4.24% | 6.48% |
Balance sheet
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $17.24M | $61.43M |
| Total Debt | $970.00K | $118.52M |
| Net Cash (Debt) | $16.27M | $15.35M |
| Net Cash Per Share | $0.43 | $0.66 |
| Equity (Book Value) | -$34.09M | $49.09M |
| Book Value Per Share | -$0.90 | $1.37 |
| Tangible Book Value | -$47.98M | $23.52M |
| Working Capital | $62.05M | $76.81M |
Financial position
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Current Ratio | 3.87 | 3.34 |
| Quick Ratio | 0.80 | 2.44 |
| Interest Coverage | -0.78 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Operating Cash Flow | -$206.00K | -$12.35M |
| Capital Expenditures | -$13.42M | -$1.08M |
| Free Cash Flow | -$13.62M | -$20.22M |
| FCF Per Share | -$0.36 | -$0.42 |
Efficiency
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Asset Turnover | 0.56 | 0.39 |
| Inventory Turnover | 3.48 | 2.70 |
| Revenue Per Employee | $337.35K | $404.87K |
| Profits Per Employee | -$101.35K | -$703.34K |
| Employee Count | 382 | 74 |
Dividends and yields
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Earnings Yield | -16.0% | -23.3% |
| FCF Yield | -5.63% | -8.72% |
| Buyback Yield | -9.86% | -0.59% |
| Shareholder Yield | -9.86% | 0.00% |
Shares
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Shares Outstanding | 37,853,100 | 58,127,000 |
| Float | 20,412,200 | 49,136,700 |
| Shares Held by Insiders | 46.1% | 11.6% |
| Shares Held by Institutions | 67.1% | 59.4% |
Taxes
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Income Tax | $43.00K | $79.87K |
Scores
| Measure | Lifecore Biomedical, Inc. De | Industry median |
|---|---|---|
| Altman Z-Score | -0.17 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Lifecore Biomedical, Inc. De's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.